Early increases in blood pressure and major adverse cardiovascular events in patients with renal cell carcinoma and thyroid cancer treated with VEGFR TKIs

Small-molecule receptor tyrosine kinase inhibitors (TKIs) targeting the VEGFR represent a mainstay systemic therapy for several advanced solid tumor malignancies. This study showed that hypertension and cardiovascular morbidities are highly prevalent among patients initiating VEGFR TKI therapies and that baseline hypertension and Black race represent the primary clinical factors associated with VEGFR TKI–related early significant hypertension.